Monday, August 21, 2017 5:23:40 PM
Citing Literature
Number of times cited: 9
1
Domen Vozel, Bojana Uršic, Judita Lea Krek, Roman Štukelj, Veronika Kralj-Iglic, Applicability of extracellular vesicles in clinical studies, European Journal of Clinical Investigation, 2017, 47, 4, 305
Wiley Online Library
2
Jennifer Oyler-Yaniv, Alon Oyler-Yaniv, Mojdeh Shakiba, Nina K. Min, Ying-Han Chen, Sheue-yann Cheng, Oleg Krichevsky, Nihal Altan-Bonnet, Grégoire Altan-Bonnet, Catch and Release of Cytokines Mediated by Tumor Phosphatidylserine Converts Transient Exposure into Long-Lived Inflammation, Molecular Cell, 2017, 66, 5, 635
CrossRef
3
Christopher D. Gregory, Catriona A. Ford, Jorine J. L. P. Voss, Apoptosis in Cancer Pathogenesis and Anti-cancer Therapy, 2016, 930, 51
CrossRef
4
Ying-Chieh Yang, Chi-Shiun Chiang, Challenges of Using High-Dose Fractionation Radiotherapy in Combination Therapy, Frontiers in Oncology, 2016, 6
CrossRef
5
David E. Gerber, David R. Spigel, David Giorgadze, Mikhail Shtivelband, Olga V. Ponomarova, Joseph S. Shan, Kerstin B. Menander, Chandra P. Belani, Docetaxel Combined With Bavituximab in Previously Treated, Advanced Nonsquamous Non–Small-Cell Lung Cancer, Clinical Lung Cancer, 2016, 17, 3, 169
CrossRef
6
S Nagata, J Suzuki, K Segawa, T Fujii, Exposure of phosphatidylserine on the cell surface, Cell Death and Differentiation, 2016, 23, 6, 952
CrossRef
7
R B Birge, S Boeltz, S Kumar, J Carlson, J Wanderley, D Calianese, M Barcinski, R A Brekken, X Huang, J T Hutchins, B Freimark, C Empig, J Mercer, A J Schroit, G Schett, M Herrmann, Phosphatidylserine is a global immunosuppressive signal in efferocytosis, infectious disease, and cancer, Cell Death and Differentiation, 2016, 23, 6, 962
CrossRef
8
Yu-Ting Cheng, Chun-Chih Yang, Lie-Fen Shyur, Phytomedicine—Modulating oxidative stress and the tumor microenvironment for cancer therapy, Pharmacological Research, 2016, 114, 128
CrossRef
9
A A Baxter, M D Hulett, I KH Poon, The phospholipid code: a key component of dying cell recognition, tumor progression and host–microbe interactions, Cell Death and Differentiation, 2015, 22, 12, 1893
Recent CDMO News
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
- Avid Bioservices Announces Proposed Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/06/2024 09:32:07 PM
- Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 03/06/2024 09:31:28 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:30:18 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/26/2024 09:57:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2024 12:34:35 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:39:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:38:30 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:37:38 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:36:27 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/12/2024 12:35:47 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/11/2024 12:56:02 AM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 01/08/2024 09:32:36 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:56:18 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:55:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:53:58 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 12:51:57 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 12/19/2023 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:34:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:33:03 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/19/2023 12:32:11 AM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM